See the following -
On the data analytics front, profound change is in the air, and open source tools are leading many of the changes. Sure, you are probably familiar with some of the open source stars in this space, such as Hadoop and Apache Spark, but there is now a strong need for new tools that can holistically round out the data analytics ecosystem. Notably, many of these tools are customized to process streaming data...Streaming data analytics are needed for improved drug discovery...While Apache Spark grabs many of the headlines in the data analytics space, given billions of development dollars thrown at it by IBM and other companies, several unsung open source projects are also on the rise. Here are three emerging data analytics tools worth exploring:
The stream of new antibiotics is struggling to keep up with emerging bacterial resistance. Anthony So and colleagues examine what can be done to increase innovation... Read More »
The final screening of the 23 shortlisted videos of CSIR-OSDD-VP Short Film Competition-2013 on “Need of New Drugs for TB” was successfully conducted by a national jury headed by veteran actor / director Shri Amol Palekar in Kolkata during 06-07 January 2013. Read More »
In the course of one short week, no less than 3 different models have emerged for sharing big data in the pharmaceutical industry. The highest profile of these ‒ called Project Data Sphere (PDS here) ‒ was announced earlier today with the official opening of an online resource to share clinical trial data for use in cancer research.
Bio-IT World announced the winners of its tenth annual Best Practices Awards competition this morning in a plenary session at the 2014 Bio-IT World Conference & Expo in Boston. Grand prize winners were named in five life sciences categories highlighting best practices in clinical trial IT, research infrastructure, bioinformatics, cloud computing and data management from AstraZeneca and Tessella, U-BIOPRED, the Pistoia Alliance, Baylor College of Medicine, and Genentech. Read More »
Transparency Life Sciences claims to be the world’s first drug development company based on open innovation. Officially launched in January 2012 it provides a platform for patients, doctors, researchers and various other stakeholders to contribute to the design of clinical studies. Read More »
As the Healthcare Information and Management Systems Society (HIMSS) 2016 theme implies -- “transforming health through IT” -- healthcare organizations are increasingly focused on taking advantage of big data to personalize the patient experience and improve clinical outcomes. Cloudera’s commitment to this effort was exemplified this morning, when the company annunced its contributions to President Obama’s Precision Medicine Initiative (PMI). By implementing Cloudera Enterprise, healthcare organizations are better equipped to deliver precision medicine with a modern data platform that facilitates information sharing across silos while remaining HIPAA-compliant...
Healthcare systems all over the world are struggling with two fundamental concerns – how to afford the rising cost of delivering care and how to integrate ever-changing new technologies? These twin challenges are intrinsically connected, for emerging technologies offer the promise of making care more affordable as well as more effective. The rewards for successful implementation will be significant, for patients as well as for those responsible for the sustainability of healthcare systems. In healthcare, the internet of things (IoT) is changing the way we think about looking after people. At the heart of this technological revolution is a focus on connectivity. Drug discovery and greater understanding of disease are critical.
The Council of Scientific and Industrial Research (CSIR)'s 'Open Source Drug Discovery' (OSDD) programme is now expanding its drug experimental capabilities. In this regard it is scouting for contract research organizations (CROs) across the country to pursue studies on tuberculosis. Read More »
Fundamentally, I think the bulk of the last decade's productivity decline is attributable to a culture problem. The Big Pharma culture has been homogenized, purified, sterilized, whipped, stirred, filtered, etc and lost its ability to ferment the good stuff required to innovate. This isn't covered in most reviews of the productivity challenge facing our industry, because its nearly impossible to quantify, but it's well known and a huge issue.
Ten years after the launch of the Bio-IT World Conference & Expo series in Boston, the conference made its debut in Asia in the sparkling Marina Bay Sands convention center. The trio of speakers who opened the three-day meeting was veteran HIV researcher David Ho, bio-IT consultant Chris Dagdigian, and AstraZeneca bioinformatician Yaron Turpaz.
Don’t we just love the fact that these days so much bioactivity data is freely available at no cost (to the end user)? I think we do. The more, the better. So, what would your answer be if someone asked you if you consider it to be a good idea if they would deposit some of their unpublished bioactivity data in ChEMBL? Read More »
Fibrodysplasia ossificans progressiva—more commonly called stone man's syndrome—is the result of a rare mutation, an anomaly in the way certain enzymes called kinases spur protein synthesis. Someone with stone man's syndrome has hyperactive kinases that catalyze more bone production than they should. The body's natural repair mechanisms malfunction, and they replace soft tissue with deposits of solid bone. Joints freeze. The body becomes a prison. But scientists know they can manipulate those kinases to combat the disease. And chemical biologists at the University of North Carolina are leading an open source effort to unlock the secrets of kinase activity—secrets they say could pioneer a new generation of drug discovery...
The Open Source Drug Discovery (OSDD) programme — a global collaborative initiative supported by the Indian government to find affordable treatment for neglected tropical diseases — has suffered a temporary setback due to a funds crunch caused by tardy submission of funding estimates. Read More »
GIA announces the release of a comprehensive global report on the E-Clinical Trial Technologies markets. The global market for E-Clinical Trial Technologies is forecast to reach US$1.37 billion by the year 2018... Read More »